Jonathan Doyle: Final Debarment Order, 40063-40064 [2021-15775]
Download as PDF
Federal Register / Vol. 86, No. 140 / Monday, July 26, 2021 / Notices
Gowns, Other Apparel, and Gloves
During the Coronavirus Disease
(COVID–19) Public Health Emergency;
Guidance for Industry and Food and
Drug Administration Staff’’ (Ref. 8).
jbell on DSKJLSW7X2PROD with NOTICES
V. References
The following references marked with
an asterisk (*) are on display at the
Dockets Management Staff (see
ADDRESSES) and are available for
viewing by interested persons between
9 a.m. and 4 p.m., Monday through
Friday; they also are available
electronically at https://
www.regulations.gov. References
without asterisks are not on public
display at https://www.regulations.gov
because they have copyright restriction.
Some may be available at the website
address, if listed. References without
asterisks are available for viewing only
at the Dockets Management Staff. FDA
has verified the website addresses, as of
the date this document publishes in the
Federal Register, but websites are
subject to change over time.
1. *Centers for Disease Control. ‘‘Perspectives
in Disease Prevention and Health
Promotion Update: Universal
Precautions for Prevention of
Transmission of Human
Immunodeficiency Virus, Hepatitis B
Virus, and Other Bloodborne Pathogens
in Health-Care Settings.’’ Morbidity and
Mortality Weekly Report 1988;
37(25):377–388.
2. World Health Organization. Glove Use
Information Leaflet. 2009. https://
www.who.int/gpsc/5may/Glove_Use_
Information_Leaflet.pdf.
3. *Collins, A.S. ‘‘Preventing Health CareAssociated Infections.’’ In: Hughes, R.G.,
editor. Patient Safety and Quality: An
Evidence-Based Handbook for Nurses.
Rockville (MD): Agency for Healthcare
Research and Quality (US); 2008 April.
Chapter 41. https://
www.ncbi.nlm.nih.gov/books/NBK2683/
pdf/Bookshelf_NBK2683.pdf.
4. Alexander, J. Wesley, Joseph S. Solomkin,
and Michael J. Edwards (2011).
‘‘Updated Recommendations for Control
of Surgical Site Infections,’’ Annals of
Surgery, 253(6):1082–1093.
5. Sugarbaker, P.H. (2018). ‘‘Increased Safety
of Surgical Glove Application: The
Under/Over Method’’ Annals of the
Royal College of Surgeons of England,
100(4):339–340.
6. Landeck, L., E. Gonzalez, and O.M. Koch.
‘‘Handling Chemotherapy Drugs—Do
Medical Gloves Really Protect?’’
International Journal of Cancer. 2015
October 15;137(8):1800–5. doi: 10.1002/
ijc.29058. Epub 2014 July 22. PMID:
24978061
7. Nalin, M., G. Hug, E. Boeckmans, C.
Machon, et al. ‘‘Permeation
Measurement of 27 Chemotherapy Drugs
After Simulated Dynamic Testing on 15
Surgical And Examination Gloves: A
Knowledge Update.’’ Journal of
VerDate Sep<11>2014
17:10 Jul 23, 2021
Jkt 253001
Oncology Pharmacy Practice. 2020 Aug
26:1078155220950423. doi: 10.1177/
1078155220950423. Epub ahead of print.
PMID: 32847481.
8. *FDA Guidance, ‘‘Enforcement Policy for
Gown, Other Apparel, and Gloves During
the Coronavirus Disease (COVID–19)
Public Health Emergency, Guidance for
Industry and Food and Drug
Administration Staff,’’ March 25, 2020,
available at https://www.fda.gov/
regulatory-information/search-fdaguidance-documents/enforcementpolicy-gowns-other-apparel-and-glovesduring-coronavirus-disease-covid-19public-health.
Dated: July 12, 2021.
Janet Woodcock,
Acting Commissioner of Food and Drugs.
Dated: July 21, 2021.
Xavier Becerra,
Secretary, Department of Health and Human
Services.
[FR Doc. 2021–15891 Filed 7–23–21; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2020–N–2149]
Jonathan Doyle: Final Debarment
Order
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is issuing an
order under the Federal Food, Drug, and
Cosmetic Act (FD&C Act) debarring
Jonathan Doyle for a period of 5 years
from importing articles of food or
offering such articles for importation
into the United States. FDA bases this
order on a finding that Mr. Doyle was
convicted of a felony count under
Federal law for conduct relating to the
importation into the United States of an
article of food. Mr. Doyle was given
notice of the proposed debarment and
an opportunity to request a hearing
within the timeframe prescribed by
regulation. As of April 8, 2021 (30 days
after receipt of the notice), Mr. Doyle
has not responded. Mr. Doyle’s failure
to respond and request a hearing
constitutes a waiver of his right to a
hearing concerning this matter.
DATES: This order is applicable July 26,
2021.
ADDRESSES: Submit applications for
termination of debarment to the Dockets
Management Staff, Food and Drug
Administration, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852, 240–402–
7500, or at https://www.regulations.gov.
SUMMARY:
PO 00000
Frm 00074
Fmt 4703
Sfmt 4703
40063
FOR FURTHER INFORMATION CONTACT:
Jaime Espinosa, Division of Enforcement
(ELEM–4029), Office of Strategic
Planning and Operational Policy, Office
of Regulatory Affairs, Food and Drug
Administration, 12420 Parklawn Dr.,
Rockville, MD 20857, 240–402–8743, or
at debarments@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
Section 306(b)(1)(C) of the FD&C Act
(21 U.S.C. 335a(b)(1)(C)) permits FDA to
debar an individual from importing an
article of food or offering such an article
for import into the United States if FDA
finds, as required by section
306(b)(3)(A) of the FD&C Act, that the
individual has been convicted of a
felony for conduct relating to the
importation into the United States of
any food.
On October 15, 2020, Mr. Doyle was
convicted as defined in section
306(l)(1)(A) of the FD&C Act, in the U.S.
District Court for the Northern District
of Texas-Dallas Division, when the court
accepted Mr. Doyle’s plea of guilty and
entered judgment against him for the
offense of conspiracy to introduce
misbranded food into interstate
commerce with an intent to defraud and
mislead in violation of 18 U.S.C. 371 (21
U.S.C. 331(a) and 21 U.S.C. 333(a)(2)).
FDA’s finding that the debarment is
appropriate is based on the felony
conviction referenced herein. The
factual basis for this conviction is as
follows: As contained in the factual
re´sume´, dated February 15, 2019, in Mr.
Doyle’s case, he was the President of
USPlabs, LLC (USP Labs), and owned 45
percent of the company. USP Labs sold
dietary supplements. Beginning in or
around October 2008 and continuing
until at least in or around August 2014,
Mr. Doyle engaged in a conspiracy with
others to import and ship in interstate
commerce a variety of chemicals for use
and prospective use in dietary
supplements with false labeling. To
further this conspiracy, Mr. Doyle’s
coconspirators ordered chemicals from
Chinese chemical sellers to be used as
ingredients in dietary supplements and
had them labeled falsely as other food
substances. USP Labs sold dietary
supplements called Jack3d and OxyElite
Pro, both of which originally contained
a substance called 1,3dimethylamylamine (DMAA), which is
also known as methylhexaneamine. USP
Labs imported numerous substances
intended for human consumption,
including DMAA, using false and
fraudulent Certificates of Analysis
(COA) and other false and fraudulent
documentation and labeling. At least
some of the false COAs that USP Labs
E:\FR\FM\26JYN1.SGM
26JYN1
jbell on DSKJLSW7X2PROD with NOTICES
40064
Federal Register / Vol. 86, No. 140 / Monday, July 26, 2021 / Notices
caused to be created for their DMAA
shipments stated falsely that the
substance in the shipments had been
extracted from the geranium plant.
Further, on or about December 8, 2011,
Mr. Doyle’s coconspirator instructed a
Chinese chemical seller via email to
misbrand a shipment of nine different
chemicals sent from China to USP Labs
in Texas. One of those synthetic
chemicals was called ‘‘aegeline.’’ The
first aegeline-containing version of
OxyElite Pro, which was called OxyElite
‘‘New Formula,’’ went on sale in
December 2012. In summer 2013, USP
Labs reformulated the product again to
contain aegeline and powder derived
from a Chinese herb called cynanchum
auriculatum. On or about June 15, 2013,
Mr. Doyle’s coconspirator instructed a
Chinese chemical seller to have two
metric tons of ground cynanchum
auriculatum root powder shipped
internationally to SK Laboratories in
California for inclusion in USP Labs’
products, using the false name
‘‘cynanchum auriculatum root extract.’’
USP Labs sent false labels listing
‘‘cynanchum auriculatum (root) extract’’
as an ingredient in its OxyElite Pro
‘‘Advanced Formula’’ supplement, even
though that ingredient was not present
in the product. The conspirators
collected millions in revenue that they
would not have obtained, absent the
conspiracy.
As a result of this conviction FDA
sent Mr. Doyle, by certified mail on
March 4, 2021, a notice proposing to
debar him for a period of 5 years from
importing articles of food or offering
such articles for import into the United
States. The proposal was based on a
finding under section 306(b)(1)(C) of the
FD&C Act that Mr. Doyle’s felony
conviction of conspiracy to introduce
misbranded food into interstate
commerce with an intent to defraud and
mislead in violation of 18 U.S.C. 371 (21
U.S.C. 331(a) and 21 U.S.C. 333(a)(2)),
constitutes conduct relating to the
importation into the United States of an
article of food because the offense
involved a conspiracy to import a
variety of chemicals with false labeling
in order to either use those chemicals in
dietary supplements which would
themselves also contain false labeling or
to determine whether those chemicals
could be used in new dietary
supplements.
The proposal was also based on a
determination, after consideration of the
relevant factors set forth in section
306(c)(3) of the FD&C Act, that Mr.
Doyle should be subject to a 5-year
period of debarment. The proposal also
offered Mr. Doyle an opportunity to
request a hearing, providing Mr. Doyle
VerDate Sep<11>2014
17:10 Jul 23, 2021
Jkt 253001
30 days from the date of receipt of the
letter in which to file the request, and
advised Mr. Doyle that failure to request
a hearing constituted a waiver of the
opportunity for a hearing and of any
contentions concerning this action. Mr.
Doyle failed to respond within the
timeframe prescribed by regulation and
has, therefore, waived his opportunity
for a hearing and waived any
contentions concerning his debarment
(21 CFR part 12).
II. Findings and Order
Therefore, the Assistant
Commissioner, Office of Human and
Animal Food Operations, under section
306(b)(1)(C) of the FD&C Act, under
authority delegated to the Assistant
Commissioner, finds that Mr. Jonathan
Doyle has been convicted of a felony
count under Federal law for conduct
relating to the importation into the
United States of an article of food and
that he is subject to a 5-year period of
debarment.
As a result of the foregoing finding,
Mr. Doyle is debarred for a period of 5
years from importing articles of food or
offering such articles for import into the
United States, effective July 26, 2021.
Pursuant to section 301(cc) of the FD&C
Act (21 U.S.C. 331(cc)), the importing or
offering for import into the United
States of an article of food by, with the
assistance of, or at the direction of
Jonathan Doyle is a prohibited act.
Any application by Mr. Doyle for
termination of debarment under section
306(d)(1) of the FD&C Act should be
identified with Docket No. FDA–2020–
N–2149 and sent to the Dockets
Management Staff (ADDRESSES). The
public availability of information in
these submissions is governed by 21
CFR 10.20.
Publicly available submissions will be
placed in the docket and will be
viewable at https://www.regulations.gov
or at the Dockets Management Staff (see
ADDRESSES) between 9 a.m. and 4 p.m.,
Monday through Friday, 240–402–7500.
Dated: July 19, 2021.
Lauren K. Roth,
Acting Principal Associate Commissioner for
Policy.
[FR Doc. 2021–15775 Filed 7–23–21; 8:45 am]
BILLING CODE 4164–01–P
PO 00000
Frm 00075
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Agency Information Collection
Activities: Proposed Collection: Public
Comment Request; Information
Collection Request Title: COVID–19
Provider Relief Fund Reporting
Activities, OMB No. 0906–XXXX New
Health Resources and Services
Administration (HRSA), Department of
Health and Human Services.
ACTION: Notice.
AGENCY:
In compliance with the
requirement for opportunity for public
comment on proposed data collection
projects of the Paperwork Reduction Act
of 1995, HRSA announces plans to
submit an Information Collection
Request (ICR), described below, to the
Office of Management and Budget
(OMB). Prior to submitting the ICR to
OMB, HRSA seeks comments from the
public regarding the burden estimate,
below, or any other aspect of the ICR.
DATES: Comments on this ICR should be
received no later than September 24,
2021.
SUMMARY:
Submit your comments to
paperwork@hrsa.gov or mail the HRSA
Information Collection Clearance
Officer, Room 14N136B, 5600 Fishers
Lane, Rockville, MD 20857.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the data collection plans and draft
instruments, email paperwork@hrsa.gov
or call Lisa Wright-Solomon, the HRSA
Information Collection Clearance Officer
at (301) 443–1984.
SUPPLEMENTARY INFORMATION: When
submitting comments or requesting
information, please include the
information request collection title for
reference.
Information Collection Request Title:
COVID–19 Provider Relief Fund
Reporting Activities, OMB No. 0906–
XXXX New.
Abstract: HRSA administers the
Provider Relief Fund (PRF), which has
disbursed funds to eligible health care
providers to support health care-related
expenses or lost revenues attributable to
the COVID–19 pandemic. Providers who
have accepted the Terms and
Conditions regarding their PRF
payment(s), including the requirement
that the provider ‘‘shall submit reports
as the Secretary determines are needed
to ensure compliance with conditions
that are imposed on this Payment, and
ADDRESSES:
E:\FR\FM\26JYN1.SGM
26JYN1
Agencies
[Federal Register Volume 86, Number 140 (Monday, July 26, 2021)]
[Notices]
[Pages 40063-40064]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-15775]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2020-N-2149]
Jonathan Doyle: Final Debarment Order
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is issuing an order
under the Federal Food, Drug, and Cosmetic Act (FD&C Act) debarring
Jonathan Doyle for a period of 5 years from importing articles of food
or offering such articles for importation into the United States. FDA
bases this order on a finding that Mr. Doyle was convicted of a felony
count under Federal law for conduct relating to the importation into
the United States of an article of food. Mr. Doyle was given notice of
the proposed debarment and an opportunity to request a hearing within
the timeframe prescribed by regulation. As of April 8, 2021 (30 days
after receipt of the notice), Mr. Doyle has not responded. Mr. Doyle's
failure to respond and request a hearing constitutes a waiver of his
right to a hearing concerning this matter.
DATES: This order is applicable July 26, 2021.
ADDRESSES: Submit applications for termination of debarment to the
Dockets Management Staff, Food and Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852, 240-402-7500, or at https://www.regulations.gov.
FOR FURTHER INFORMATION CONTACT: Jaime Espinosa, Division of
Enforcement (ELEM-4029), Office of Strategic Planning and Operational
Policy, Office of Regulatory Affairs, Food and Drug Administration,
12420 Parklawn Dr., Rockville, MD 20857, 240-402-8743, or at
[email protected].
SUPPLEMENTARY INFORMATION:
I. Background
Section 306(b)(1)(C) of the FD&C Act (21 U.S.C. 335a(b)(1)(C))
permits FDA to debar an individual from importing an article of food or
offering such an article for import into the United States if FDA
finds, as required by section 306(b)(3)(A) of the FD&C Act, that the
individual has been convicted of a felony for conduct relating to the
importation into the United States of any food.
On October 15, 2020, Mr. Doyle was convicted as defined in section
306(l)(1)(A) of the FD&C Act, in the U.S. District Court for the
Northern District of Texas-Dallas Division, when the court accepted Mr.
Doyle's plea of guilty and entered judgment against him for the offense
of conspiracy to introduce misbranded food into interstate commerce
with an intent to defraud and mislead in violation of 18 U.S.C. 371 (21
U.S.C. 331(a) and 21 U.S.C. 333(a)(2)).
FDA's finding that the debarment is appropriate is based on the
felony conviction referenced herein. The factual basis for this
conviction is as follows: As contained in the factual
r[eacute]sum[eacute], dated February 15, 2019, in Mr. Doyle's case, he
was the President of USPlabs, LLC (USP Labs), and owned 45 percent of
the company. USP Labs sold dietary supplements. Beginning in or around
October 2008 and continuing until at least in or around August 2014,
Mr. Doyle engaged in a conspiracy with others to import and ship in
interstate commerce a variety of chemicals for use and prospective use
in dietary supplements with false labeling. To further this conspiracy,
Mr. Doyle's coconspirators ordered chemicals from Chinese chemical
sellers to be used as ingredients in dietary supplements and had them
labeled falsely as other food substances. USP Labs sold dietary
supplements called Jack3d and OxyElite Pro, both of which originally
contained a substance called 1,3-dimethylamylamine (DMAA), which is
also known as methylhexaneamine. USP Labs imported numerous substances
intended for human consumption, including DMAA, using false and
fraudulent Certificates of Analysis (COA) and other false and
fraudulent documentation and labeling. At least some of the false COAs
that USP Labs
[[Page 40064]]
caused to be created for their DMAA shipments stated falsely that the
substance in the shipments had been extracted from the geranium plant.
Further, on or about December 8, 2011, Mr. Doyle's coconspirator
instructed a Chinese chemical seller via email to misbrand a shipment
of nine different chemicals sent from China to USP Labs in Texas. One
of those synthetic chemicals was called ``aegeline.'' The first
aegeline-containing version of OxyElite Pro, which was called OxyElite
``New Formula,'' went on sale in December 2012. In summer 2013, USP
Labs reformulated the product again to contain aegeline and powder
derived from a Chinese herb called cynanchum auriculatum. On or about
June 15, 2013, Mr. Doyle's coconspirator instructed a Chinese chemical
seller to have two metric tons of ground cynanchum auriculatum root
powder shipped internationally to SK Laboratories in California for
inclusion in USP Labs' products, using the false name ``cynanchum
auriculatum root extract.'' USP Labs sent false labels listing
``cynanchum auriculatum (root) extract'' as an ingredient in its
OxyElite Pro ``Advanced Formula'' supplement, even though that
ingredient was not present in the product. The conspirators collected
millions in revenue that they would not have obtained, absent the
conspiracy.
As a result of this conviction FDA sent Mr. Doyle, by certified
mail on March 4, 2021, a notice proposing to debar him for a period of
5 years from importing articles of food or offering such articles for
import into the United States. The proposal was based on a finding
under section 306(b)(1)(C) of the FD&C Act that Mr. Doyle's felony
conviction of conspiracy to introduce misbranded food into interstate
commerce with an intent to defraud and mislead in violation of 18
U.S.C. 371 (21 U.S.C. 331(a) and 21 U.S.C. 333(a)(2)), constitutes
conduct relating to the importation into the United States of an
article of food because the offense involved a conspiracy to import a
variety of chemicals with false labeling in order to either use those
chemicals in dietary supplements which would themselves also contain
false labeling or to determine whether those chemicals could be used in
new dietary supplements.
The proposal was also based on a determination, after consideration
of the relevant factors set forth in section 306(c)(3) of the FD&C Act,
that Mr. Doyle should be subject to a 5-year period of debarment. The
proposal also offered Mr. Doyle an opportunity to request a hearing,
providing Mr. Doyle 30 days from the date of receipt of the letter in
which to file the request, and advised Mr. Doyle that failure to
request a hearing constituted a waiver of the opportunity for a hearing
and of any contentions concerning this action. Mr. Doyle failed to
respond within the timeframe prescribed by regulation and has,
therefore, waived his opportunity for a hearing and waived any
contentions concerning his debarment (21 CFR part 12).
II. Findings and Order
Therefore, the Assistant Commissioner, Office of Human and Animal
Food Operations, under section 306(b)(1)(C) of the FD&C Act, under
authority delegated to the Assistant Commissioner, finds that Mr.
Jonathan Doyle has been convicted of a felony count under Federal law
for conduct relating to the importation into the United States of an
article of food and that he is subject to a 5-year period of debarment.
As a result of the foregoing finding, Mr. Doyle is debarred for a
period of 5 years from importing articles of food or offering such
articles for import into the United States, effective July 26, 2021.
Pursuant to section 301(cc) of the FD&C Act (21 U.S.C. 331(cc)), the
importing or offering for import into the United States of an article
of food by, with the assistance of, or at the direction of Jonathan
Doyle is a prohibited act.
Any application by Mr. Doyle for termination of debarment under
section 306(d)(1) of the FD&C Act should be identified with Docket No.
FDA-2020-N-2149 and sent to the Dockets Management Staff (ADDRESSES).
The public availability of information in these submissions is governed
by 21 CFR 10.20.
Publicly available submissions will be placed in the docket and
will be viewable at https://www.regulations.gov or at the Dockets
Management Staff (see ADDRESSES) between 9 a.m. and 4 p.m., Monday
through Friday, 240-402-7500.
Dated: July 19, 2021.
Lauren K. Roth,
Acting Principal Associate Commissioner for Policy.
[FR Doc. 2021-15775 Filed 7-23-21; 8:45 am]
BILLING CODE 4164-01-P